Friday August 28, 2015
Israel Hayom
About Us The Hebrew Print Edition Areas of Distribution Vision History Advertising Contact Us
> Newsletters from:
Send to a Friend | Print |
Israeli biotech company sold for $480 million

OPKO Health Inc. chairman Dr. Phillip Frost: "Prolor's drug-product candidates for growth hormone deficiency, hemophilia, obesity and diabetes ... are highly valuable assets that will complement OPKO's strategy."

Hezi Sternlicht and Reuters

Photo credit: Prolor's website
Back to home page | Newsletters from: